Oral anti-hyperalgesic and anti-inflammatory activity of NK1 receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig

[1]  M S Kramer,et al.  Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. , 1999, Trends in pharmacological sciences.

[2]  L. Urbán,et al.  Selective neurokinin-1 receptor antagonists are anti-hyperalgesic in a model of neuropathic pain in the guinea-pig , 1998, Neuroscience.

[3]  C. Woolf,et al.  Null Mutations Lacking Substance: Elucidating Pain Mechanisms by Genetic Pharmacology , 1998, Neuron.

[4]  P. McIntyre,et al.  Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist , 1998, British journal of pharmacology.

[5]  X. Hua,et al.  Spinal Neurokinin NK1 Receptor Down‐Regulation and Antinociception: Effects of Spinal NK1 Receptor Antisense Oligonucleotides and NK1 Receptor Occupancy , 1998, Journal of neurochemistry.

[6]  C. Maggi,et al.  The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles , 1998, Neuropeptides.

[7]  J. Howbert,et al.  Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist. , 1995, The Journal of pharmacology and experimental therapeutics.

[8]  S. Boyce,et al.  Antinociceptive activity of the tachykinin NK1 receptor antagonist, CP‐99,994, in conscious gerbils , 1995, British journal of pharmacology.

[9]  M. Millan,et al.  Antinociceptive profiles of non-peptidergic neurokinin1 and neurokinin2 receptor antagonists: a comparison to other classes of antinociceptive agent , 1995, Pain.

[10]  P. Andrews,et al.  The anti‐emetic effects of CP‐99,994 in the ferret and the dog: role of the NK1 receptor , 1995, British journal of pharmacology.

[11]  P. Geppetti,et al.  Involvement of tachykinins in plasma extravasation induced by bradykinin and low pH medium in the guinea‐pig conjunctiva , 1995, British journal of pharmacology.

[12]  S. Nourshargh,et al.  Substance P‐induced inflammatory responses in guinea‐pig skin: The effect of specific NK1 receptor antagonists and the role of endogenous mediators , 1995, British journal of pharmacology.

[13]  L. Urbán,et al.  Modulation of spinal excitability: co-operation between neurokinin and excitatory amino acid neurotransmitters , 1994, Trends in Neurosciences.

[14]  S. Harrison,et al.  Non-specific effects of the tachykinin NK1 receptor antagonist, CP-99,994, in antinociceptive tests in rat, mouse and gerbil. , 1994, European journal of pharmacology.

[15]  N. Rupniak,et al.  Differential inhibition of foot tapping and chromodacryorrhoea in gerbils by CNS penetrant and non-penetrant tachykinin NK1 receptor antagonists. , 1994, European journal of pharmacology.

[16]  S. Cruwys,et al.  The role of bradykinin B1 receptors in the maintenance of intra‐articular plasma extravasation in chronic antigen‐induced arthritis , 1994, British journal of pharmacology.

[17]  S. H. Buck.  The Tachykinin Receptors , 1994, The Receptors.

[18]  L. Urbán,et al.  Injury-induced plasticity of spinal reflex activity: NK1 neurokinin receptor activation and enhanced A- and C-fiber mediated responses in the rat spinal cord in vitro , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[19]  C. Garret,et al.  In vivo pharmacological properties of RPR100893, a novel non-peptide antagonist of the human NK1 receptor , 1994, Neuropeptides.

[20]  G. Fur,et al.  Involvement of tachykinins in the bronchospasm induced by chemicals in the guinea-pig. Inhibition by SR48968 , 1994, Neuropeptides.

[21]  M. Spedding,et al.  Differential effects of non-peptidic tachykinin receptor antagonists on Ca2+ channels. , 1994, European journal of pharmacology.

[22]  L. Bristow,et al.  Chromodacryorrhea and repetitive hind paw tapping: models of peripheral and central tachykinin NK1 receptor activation in gerbils. , 1994, European journal of pharmacology.

[23]  K. McCarson,et al.  NK-1 and NK-3 type tachykinin receptor mRNA expression in the rat spinal cord dorsal horn is increased during adjuvant or formalin- induced nociception , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[24]  J. Krause,et al.  Molecular Biology of Receptors , 1994 .

[25]  C. Maggi.  Evidence for Receptor Subtypes/Species Variants of Receptors , 1994 .

[26]  P. Soubrié,et al.  In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist. , 1993, European journal of pharmacology.

[27]  S. Iversen,et al.  Antinociceptive activity of NK1 receptor antagonists: non‐specific effects of racemic RP67580 , 1993, British journal of pharmacology.

[28]  A. Ganong,et al.  Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. , 1993, The Journal of pharmacology and experimental therapeutics.

[29]  A. Eschalier,et al.  RP-67580, a specific tachykinin NK1 receptor antagonist, relieves chronic hyperalgesia in diabetic rats. , 1993, European journal of pharmacology.

[30]  S. Guard,et al.  The interaction of the NK1 receptor antagonist CP‐96,345 with L‐type calcium channels and its functional consequences , 1993, British journal of pharmacology.

[31]  J. Kemp,et al.  Block of voltage‐dependent sodium currents by the substance P receptor antagonist (±)‐CP‐96,345 in neurones cultured from rat cortex , 1993, British journal of pharmacology.

[32]  C. Maggi,et al.  Tachykinin receptors and tachykinin receptor antagonists. , 1993, Journal of autonomic pharmacology.

[33]  A. Barr,et al.  Non‐peptide antagonists, CP‐96,345 and RP 67580, distinguish species variants in tachykinin NK1 receptors , 1993, British journal of pharmacology.

[34]  A. Murase,et al.  Non‐specific activity of (±)‐CP‐96,345 in models of pain and inflammation , 1992, Regulatory peptides.

[35]  Z. Wiesenfeld‐Hallin,et al.  Spinal substance p and N-methyl-d-aspartate receptors are coactivated in the induction of central sensitization of the nociceptive flexor reflex , 1992, Neuroscience.

[36]  Anne W. Schmidt,et al.  The substance P receptor antagonist CP-96,345 interacts with Ca2+ channels. , 1992, European journal of pharmacology.

[37]  J. Lowe,et al.  Antiinflammatory and analgesic activity of a non-peptide substance P receptor antagonist , 1992, Regulatory Peptides.

[38]  S. Harrison,et al.  The non‐peptide NK1 receptor antagonist, (±)‐CP‐96,345, produces antinociceptive and anti‐oedema effects in the rat , 1992, British journal of pharmacology.

[39]  P. Laduron,et al.  Pharmacological properties of a potent and selective nonpeptide substance P antagonist. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Henry,et al.  Novel substance P antagonist, CP-96,345, blocks responses of cat spinal dorsal horn neurons to noxious cutaneous stimulation and to substance P , 1991, Neuroscience Letters.

[41]  R. Hagan,et al.  Investigation into species variants in tachykinin NK1 receptors by use of the non‐peptide antagonist, CP‐96,345 , 1991, British journal of pharmacology.

[42]  J. Howbert,et al.  Species differences in affinities of non-peptide antagonists for substance P receptors. , 1991, European journal of pharmacology.

[43]  J. Lowe,et al.  A potent nonpeptide antagonist of the substance P (NK1) receptor. , 1991, Science.

[44]  T. Yamamoto,et al.  Stereospecific effects of a nonpeptidic NK1 selective antagonist, CP-96,345: antinociception in the absence of motor dysfunction. , 1991, Life sciences.

[45]  H. Schaible,et al.  Release of immunoreactive substance P in the spinal cord during development of acute arthritis in the knee joint of the cat: a study with antibody microprobes , 1990, Brain Research.

[46]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[47]  J. Truax,et al.  Quantitative comparison of the analgesic and anti-inflammatory activities of aspirin, phenacetin and acetaminophen in rodents. , 1976, European journal of pharmacology.